335 related articles for article (PubMed ID: 24703319)
1. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
2. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lambrechts D; Claes B; Delmar P; Reumers J; Mazzone M; Yesilyurt BT; Devlieger R; Verslype C; Tejpar S; Wildiers H; de Haas S; Carmeliet P; Scherer SJ; Van Cutsem E
Lancet Oncol; 2012 Jul; 13(7):724-33. PubMed ID: 22608783
[TBL] [Abstract][Full Text] [Related]
3. Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.
Pectasides D; Papaxoinis G; Kotoula V; Fountzilas H; Korantzis I; Koutras A; Dimopoulos AM; Papakostas P; Aravantinos G; Varthalitis I; Kosmidis P; Skarlos D; Bournakis E; Bafaloukos D; Kalofonos HP; Kalogeras KT; Fountzilas G
Oncol Rep; 2012 Jan; 27(1):216-24. PubMed ID: 22025320
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
6. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
7. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.
Hegde PS; Jubb AM; Chen D; Li NF; Meng YG; Bernaards C; Elliott R; Scherer SJ; Chen DS
Clin Cancer Res; 2013 Feb; 19(4):929-37. PubMed ID: 23169435
[TBL] [Abstract][Full Text] [Related]
8. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for advanced breast cancer.
Goldfarb SB; Traina TA; Dickler MN
Womens Health (Lond); 2010 Jan; 6(1):17-25. PubMed ID: 20001867
[TBL] [Abstract][Full Text] [Related]
11. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
12. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in the treatment of metastatic breast cancer.
Traina TA
Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
[TBL] [Abstract][Full Text] [Related]
15. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
16. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
[TBL] [Abstract][Full Text] [Related]
17. Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.
Kourea HP; Kotoula V; Koutras A; Alexopoulou Z; Papaspirou I; Skarlos DV; Efstratiou I; Bobos M; Zagouri F; Papakostas P; Pectasides D; Chrisafi S; Varthalitis I; Aravantinos G; Kosmidis P; Bafaloukos D; Scopa CD; Fountzilas G
Histol Histopathol; 2015 Sep; 30(9):1129-41. PubMed ID: 25807307
[TBL] [Abstract][Full Text] [Related]
18. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
Bates DO; Catalano PJ; Symonds KE; Varey AH; Ramani P; O'Dwyer PJ; Giantonio BJ; Meropol NJ; Benson AB; Harper SJ
Clin Cancer Res; 2012 Nov; 18(22):6384-91. PubMed ID: 23104894
[TBL] [Abstract][Full Text] [Related]
19. VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma.
D'Alessandris QG; Martini M; Cenci T; Capo G; Ricci-Vitiani L; Larocca LM; Pallini R
Neurology; 2015 May; 84(18):1906-8. PubMed ID: 25862796
[No Abstract] [Full Text] [Related]
20. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
